Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Regeneron’s EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly…
EyePoint receives second consecutive positive recommendation from DSMC | Ophthalmology Times
(Image credit: ©peopleimages.com/AdobeStock) The Data Safety Monitoring Committee (DSMC) recently completed its second scheduled review of EyePoint Pharmaceuticals’ ongoing phase 3 trial evaluating DURAVYU for the treatment of wet AMD (wAMD), EyePoint announced.1 The DSMC concluded that both the LUGANO…
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant | Ophthalmology Times
(Image Credit: AdobeStock/Anna) Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical Center in Haifa, Israel. The procedure was conducted as part of the company’s ongoing phase 1 clinical trial. PB-001 is…
Limitations of Current Dry Eye Therapies | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Treatment Selection in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Prolonged digital device use increases risk of headaches, eye pain, and fatigue in children | Ophthalmology Times
(Image Credit: AdobeStock/NVB Stocker) A recent analysis examining the effects of screen time on the pediatric population has found that excessive use of digital devices can lead to both short- and long-term negative health outcomes. The analysis drew on a…
Harrow completes acquisiton of Melt Pharmaceuticals | Ophthalmology Times
(Image Credit: AdobeStock/Parradee) Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and MELT-400 based on the Zydis ODT (oral dissolving tablet) drug delivery platform. Melt will now be fully integrated into Harrow’s operations to…
Coave Therapeutics reveals lead gene therapy program, CoTx-101 | Ophthalmology Times
(Image Credit: AdobeStock) Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The company describes CoTx-101 as the combination of…
Brain Stimulation Boosts Vision Recovery After Stroke
A new study from researchers at EPFL introduces a promising non-invasive brain stimulation technique aimed at restoring visual function in stroke patients with hemianopia. The treatment combines visual training with targeted neuromodulation, offering a novel approach to visual rehabilitation in…
Trifocal IOL for Presbyopia Correction
Presbyopia continues to be one of the most significant visual limitations following cataract surgery, even with the use of advanced monofocal or extended-depth intraocular lenses (IOLs). Despite technological progress, achieving consistent vision across near, intermediate and far distance foci remains…